FDA Issues Complete Response Letter for ¹⁷⁷Lu-Edotreotide in GEP-NETs: FDA Regulatory Update | August 2026

Introduction:

Radioligand therapy is becoming increasingly important in somatostatin receptor–positive neuroendocrine tumors. The FDA has issued a Complete Response Letter (CRL) for ¹⁷⁷Lu-edotreotide (ITM-11) in advanced GEP-NETs. Importantly, the decision appears to reflect manufacturing and facility-related issues rather than concerns about clinical efficacy or safety.

Why is this important?

A CRL means the application cannot be approved in its current form; it does not necessarily mean the drug itself has failed.

The FDA cited chemistry, manufacturing and controls (CMC) and third-party commercial facility issues requiring remediation.

No clinical or nonclinical efficacy or safety concerns were identified in the CRL, according to the developer.

ITM intends to address the deficiencies and resubmit the application.

What did COMPETE show?

The phase III COMPETE trial enrolled 309 patients with progressive, inoperable, grade 1–2, SSTR-positive gastroenteric or pancreatic NETs.

Median PFS was 23.9 months with ¹⁷⁷Lu-edotreotide vs 14.1 months with everolimus (HR 0.67).

Objective response was also higher: 21.9% vs 4.2% by central assessment.

Interim OS was numerically longer (63.4 vs 58.7 months) but not statistically significant, while quality-of-life outcomes favored ¹⁷⁷Lu-edotreotide.

Clinical Impact:

The regulatory distinction is crucial:

Positive phase III clinical evidence ≠ automatic regulatory approval.

Radiopharmaceuticals have particularly demanding requirements for isotope production, manufacturing consistency, quality control, logistics, and commercial-site compliance. Thus, the current setback appears regulatory/manufacturing rather than a rejection of the therapeutic concept.

The findings also add to growing evidence supporting earlier radioligand therapy in SSTR-positive GEP-NETs, alongside the evolving evidence from NETTER-2.

Bottom Line:

The FDA has not approved ¹⁷⁷Lu-edotreotide for GEP-NETs and issued a Complete Response Letter because of CMC and manufacturing-facility deficiencies—not identified efficacy or safety concerns. With COMPETE showing significantly longer PFS than everolimus, the key next step is remediation and NDA resubmission rather than generation of an entirely new efficacy signal.